You can buy or sell SBPH and other stocks, options, ETFs, and crypto commission-free!
Spring Bank Pharmaceuticals, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. Read More The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA.
52 Week High
52 Week Low
Spring Bank Pharmaceuticals Reports First Quarter 2019 Financial and Operational Results and Provides Corporate Update
ACHIEVE trial completed - inarigivir HBsAg reduction comparable to interferon but with significantly better tolerability profile Phase 2 co-administration study of inarigivir + nucleotide analogue fully enrolled - top-line results expected 2H'19 Study results to be presented at Science of HBV Cure meeting in Singapore demonstrating immune activation of inarigivir 400mg without systemic cytokine toxicity CATALYST Phase 2b trials launched - designed to demonstrate functional cure in HBV On track to ...
Expected Jul 31, After Hours